PhRMA Urges FTC Not To Expand Patent Licensing Scrutiny

Law360, New York (November 1, 2012, 5:52 PM EDT) -- The Pharmaceutical Research and Manufacturers of America accused the Federal Trade Commission on Wednesday of exceeding its authority under federal merger law and discriminating against the industry by proposing to expand the types of exclusive pharmaceutical patent rights licenses that require antitrust approval.

The trade group, which goes by the acronym PhRMA, urged the FTC to abandon its plans to amend its premerger notification rules governing what types of exclusive patent rights transfers require antitrust approval, saying it unfairly singled out the pharmaceutical industry for heavier...
To view the full article, register now.